Ozawa Heita, Kotake Kenjiro, Hosaka Miki, Hirata Akira, Sugihara Kenichi
Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, 113-8519, Tokyo, Japan.
World J Surg. 2016 Jun;40(6):1492-9. doi: 10.1007/s00268-016-3444-y.
The aim of this study was to clarify the survival benefit of lateral pelvic lymph node dissection (LPLND) for patients with pathological T3 and T4 (pT3/T4) low rectal cancer.
We evaluated the impact of LPLND on survival for pT3/T4 low rectal cancer patients. The primary endpoint of the study was overall survival (OS). The large-scale database of the Japanese Society for Cancer of the Colon and Rectum registration system was accessed and the data were analyzed using a propensity score matching method based on the likelihood of receiving LPLND. Using seven covariates, the propensity scores were calculated with multivariate logistic regression. A total of 499 propensity score-matched pairs of patients were selected from the entire cohort of 1,840 patients who had received curative resection for pT3/T4 low rectal cancer between 1995 and 2004.
In the matched cohort, the 5-year OS of the patients who had and had not undergone LPLND were 68.9 and 62.0 %, respectively (p = 0.013; hazard ratio [HR], 0.755; 95 % confidence interval [CI], 0.604-0.944). The 5-year OS of the patients with node-negative disease who had and had not received LPLND differed statistically significantly (5-year OS were 82.1 and 71.4 %, respectively. p = 0.006; HR, 0.579; 95 % CI 0.389-0.862). However, those with node-positive disease did not differ significantly (5-year OS were 55.5 and 53.8 %, respectively. p = 0.415; HR 0.893; 95 % CI 0.681-1.172).
The impact of LPLND on OS for patients with node-negative pT3/T4 low rectal cancer was suggested in this retrospective cohort study. To determine true benefits and harms of LPLND, further prospective studies may be warranted.
本研究旨在阐明侧方盆腔淋巴结清扫术(LPLND)对病理T3和T4(pT3/T4)期低位直肠癌患者的生存获益情况。
我们评估了LPLND对pT3/T4期低位直肠癌患者生存的影响。本研究的主要终点为总生存期(OS)。我们访问了日本结直肠癌学会登记系统的大规模数据库,并使用基于接受LPLND可能性的倾向评分匹配方法对数据进行分析。利用七个协变量,通过多变量逻辑回归计算倾向评分。从1995年至2004年间接受pT3/T4期低位直肠癌根治性切除术的1840例患者的整个队列中,共选取了499对倾向评分匹配的患者。
在匹配队列中,接受和未接受LPLND的患者5年总生存率分别为68.9%和62.0%(p = 0.013;风险比[HR],0.755;95%置信区间[CI],0.604 - 0.944)。淋巴结阴性疾病患者接受和未接受LPLND的5年总生存率在统计学上有显著差异(5年总生存率分别为82.1%和71.4%。p = 0.006;HR,0.579;95%CI 0.389 - 0.862)。然而,淋巴结阳性疾病患者之间无显著差异(5年总生存率分别为55.5%和53.8%。p = 0.415;HR 0.893;95%CI 0.681 - 1.172)。
这项回顾性队列研究表明LPLND对淋巴结阴性的pT3/T4期低位直肠癌患者的总生存期有影响。为确定LPLND的真正益处和危害,可能需要进一步的前瞻性研究。